China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Allam was serving recently as the CEO at Public Investment Fund
Positive opinions based on significant survival benefit
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The investment will enable the company to enter European markets as well as enhance margins in current markets
Subscribe To Our Newsletter & Stay Updated